Table 1 General and clinicopathological characteristics of patients ( n = 12)
Patient no. | Sex | Diagnosis | Regimen | Treatment number | Clinical efficacy |
|---|---|---|---|---|---|
1 | Male | Colon cancer metastases to liver | C225 + FOLFIRI | 3 | PD |
2 | Male | Rectal cancer metastases to liver | C225 + CPT-11 | 3 | PD |
3 | Male | Rectal cancer metastases to liver | C225 + FOLFOX | 2 | PD |
4 | Male | Rectal cancer metastases to LN | C225 + FOLFIRI | 3 | PD |
5 | Male | Colon cancer metastases to liver | C225 + XELOX | 4 | SD |
6 | Male | Rectal cancer metastases to liver | C225 + CPT-11 | 18 | PR |
7 | Male | Rectal cancer metastases to liver | C225 + FOLFOX | 5 | PR |
8 | Male | Rectal cancer metastases to liver | C225 + FOLFOX | 1 | PR |
9 | Male | Colon cancer metastases to liver | C225 + FOLFOX | 12 | PR |
10 | Male | Colon cancer metastases to liver | C225 + FOLFOX | 12 | PR |
11 | Male | Colon cancer metastases to liver | C225 + FOLFIRI | 3 | PR |
12 | Female | Colon cancer metastases to liver | C225 + FOLFIRI | 3 | PR |